פאפאוורין טבע להזרקה
teva israel ltd - papaverine hydrochloride - תמיסה להזרקה - papaverine hydrochloride 40 mg / 2 ml - papaverine - papaverine - antispasmodic in visceral spasm, e.g. gastrointestinal colic, biliary and urinary tract spasms. peripheral vascular disease with vasospastic element. vascular spasm associated with acute myocardial infarcion, angina pectoris, peripheral and pulmonary embolism.
דומיטור וטרינרי
pfizer pharmaceuticals israel ltd - medetomidine hydrochloride 1 mg/ml - solution for injection - dogs:for restraint, sedation and analgesia associated with clinical examinations and procedures, minor surgery and pre-anaesthesia.as a premedicant before thiopentone, halothane general anaesthesia and as a premedicant before general anaesthesia with propofol.cats:for restraint and sedation.in combination with ketamine for induction of general anaesthesia prior to surgical procedures.
אנטיסדן וטרינרי
zoetis israel holding b.v., israel - atipamezole hydrochloride - תמיסה להזרקה - atipamezole hydrochloride 5 mg/ml
טרגין 40
rafa laboratories ltd - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - טבליות בשחרור ממושך - naloxone hydrochloride (as dihydrate) 20 mg; oxycodone hydrochloride 40 mg - naloxone - naloxone - targin is indicated for the relief of moderate to severe pain.the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut
טרגין 10
rafa laboratories ltd - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - טבליות בשחרור ממושך - oxycodone hydrochloride 10 mg; naloxone hydrochloride (as dihydrate) 5 mg - naloxone - naloxone - targin is indicated for the relief of moderate to severe pain.the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut
טרגין 20
rafa laboratories ltd - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - טבליות בשחרור ממושך - oxycodone hydrochloride 20 mg; naloxone hydrochloride (as dihydrate) 10 mg - naloxone - naloxone - targin is indicated for the relief of moderate to severe pain.the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut
טרגין 5
rafa laboratories ltd - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - טבליות בשחרור ממושך - oxycodone hydrochloride 5 mg; naloxone hydrochloride (as dihydrate) 2.5 mg - naloxone - naloxone - targin is indicated for the relief of moderate to severe pain.the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.
טרגין 30
rafa laboratories ltd - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - טבליות בשחרור ממושך - naloxone hydrochloride (as dihydrate) 15 mg; oxycodone hydrochloride 30 mg - oxycodone and naloxone
ניקסואיד 1.8 מג
rafa laboratories ltd - naloxone as hydrochloride dihydrate - תמיסה - naloxone as hydrochloride dihydrate 1.8 mg / 0.1 ml - naloxone
סובוקסון 2 מג 0.5 מג
naomi shaco-ezra ltd - buprenorphine hydrochloride; naloxone hydrochloride dihydrate - טבליות למתן מתחת ללשון - buprenorphine hydrochloride 2.16 mg; naloxone hydrochloride dihydrate 0.61 mg - buprenorphine - buprenorphine - substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. the intention of the naloxone component is to deter intravenous misuse.treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction.